Helix BioPharma Corp
- LAST PRICE0.7100
- TODAY'S CHANGE (%)-0.0500 (-6.5789%)
- Bid / Lots0.6000/ 6
- Ask / Lots0.7100/ 2
- Open / Previous Close0.7500 / 0.7600
- Day Range
- 52 Week Range
- Volume3,250
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HBP |
|---|---|---|
| 09:32 ET | 500 | 0.75 |
| 09:33 ET | 2000 | 0.75 |
| 11:43 ET | 500 | 0.71 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Helix BioPharma Corp | 37.3M | -3.6x | --- |
KDA Group Inc | 39.5M | -80.9x | --- |
Sona Nanotech Inc | 29.0M | -8.4x | --- |
Defence Therapeutics Inc | 28.2M | -2.1x | --- |
Thiogenesis Therapeutics Corp | 27.3M | -5.5x | --- |
Biomind Labs Inc | 35.7M | -31.1x | --- |
Company Information
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
Contact Information
- Headquarters
- Bay Adelaide Centre - North Tower 40 Temperance Street, Suite 2700 TorontoTORONTO, ON, Canada M5H 0B4
- Phone
- 604-684-2181
- Fax
- 905-841-2244
Executives
- Independent Director
- Jacek Antas
- Chief Financial Officer
- Hatem Kawar
- Independent Director
- Margaret Laube
- Independent Director
- Jerzy Leszczynski
- Independent Director
- Christopher Maciejewski
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.84 |
EPS | $-0.20 |
Book Value | $0.00 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
